Clinical Trial Update: Study of Reactogenicity, Safety, Immunogenicity, and Pock Lesion Formation of a Cell-Cultured Smallpox Vaccine Compared to Dryvax® [Phase 1]

View source ↗

Summary

Phase 1 trial comparing a cell-cultured smallpox vaccine to Dryvax, evaluating safety, reactogenicity, immunogenicity, and pock lesion formation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Smallpox

Drugs mentioned

• ACAM2000 (Vaccinia vaccine (live, cell culture-derived))
• Dryvax (Vaccinia virus vaccine)

Snippet

Sponsor: DynPort Vaccine Company LLC, A GDIT Company | Conditions: Smallpox | Phase 1 | Status: COMPLETED